Family Megaosophagus
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Modified Heller´S Esophageal Myotomy Associated with Dor's
Crimson Publishers Research Article Wings to the Research Modified Heller´s Esophageal Myotomy Associated with Dor’s Fundoplication A Surgical Alternative for the Treatment of Dolico Megaesophagus Fernando Athayde Veloso Madureira*, Francisco Alberto Vela Cabrera, Vernaza ISSN: 2637-7632 Monsalve M, Moreno Cando J, Charuri Furtado L and Isis Wanderley De Sena Schramm Department of General Surgery, Brazil Abstracts The most performed surgery for the treatment of achalasia is Heller´s esophageal myotomy associated or no with anti-reflux fundoplication. We propose in cases of advanced megaesophagus, specifically in the dolico megaesophagus, a technical variation. The aim of this study was to describe Heller´s myotomy modified by Madureira associated with Dor´s fundoplication as an alternative for the treatment of dolico megaesophagus,Materials and methods: assessing its effectiveness at through dysphagia scores and quality of life questionnaires. *Corresponding author: proposes the dissection ofTechnical the esophagus Note describing intrathoracic, the withsurgical circumferential procedure and release presenting of it, in the the results most of three patients with advanced dolico megaesophagus, operated from 2014 to 2017. The technique A. V. Madureira F, MsC, Phd. Americas Medical City Department of General extensive possible by trans hiatal route. Then the esophagus is retracted and fixed circumferentially in the Surgery, Full Professor of General pillars of the diaphragm with six or seven point. The goal is at least on the third part of the esophagus, to achieveResults: its broad mobilization and rectification of it; then is added a traditional Heller myotomy. Submission:Surgery At UNIRIO and PUC- Rio, Brazil Published: The mean dysphagia score in pre-op was 10points and in the post- op was 1.3 points (maximum October 09, 2019 of 10 points being observed each between the pre and postoperative 8.67 points, 86.7%) The mean October 24, 2019 hospitalization time was one day. -
Peripheral Neuropathy in Complex Inherited Diseases: an Approach To
PERIPHERAL NEUROPATHY IN COMPLEX INHERITED DISEASES: AN APPROACH TO DIAGNOSIS Rossor AM1*, Carr AS1*, Devine H1, Chandrashekar H2, Pelayo-Negro AL1, Pareyson D3, Shy ME4, Scherer SS5, Reilly MM1. 1. MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, UK. 2. Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, London, WC1N 3BG, UK. 3. Unit of Neurological Rare Diseases of Adulthood, Carlo Besta Neurological Institute IRCCS Foundation, Milan, Italy. 4. Department of Neurology, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA 5. Department of Neurology, University of Pennsylvania, Philadelphia, PA 19014, USA. * These authors contributed equally to this work Corresponding author: Mary M Reilly Address: MRC Centre for Neuromuscular Diseases, 8-11 Queen Square, London, WC1N 3BG, UK. Email: [email protected] Telephone: 0044 (0) 203 456 7890 Word count: 4825 ABSTRACT Peripheral neuropathy is a common finding in patients with complex inherited neurological diseases and may be subclinical or a major component of the phenotype. This review aims to provide a clinical approach to the diagnosis of this complex group of patients by addressing key questions including the predominant neurological syndrome associated with the neuropathy e.g. spasticity, the type of neuropathy, and the other neurological and non- neurological features of the syndrome. Priority is given to the diagnosis of treatable conditions. Using this approach, we associated neuropathy with one of three major syndromic categories - 1) ataxia, 2) spasticity, and 3) global neurodevelopmental impairment. Syndromes that do not fall easily into one of these three categories can be grouped according to the predominant system involved in addition to the neuropathy e.g. -
Premature Loss of Permanent Teeth in Allgrove (4A) Syndrome in Two Related Families
Iran J Pediatr Case Report Mar 2010; Vol 20 (No 1), Pp:101-106 Premature Loss of Permanent Teeth in Allgrove (4A) Syndrome in Two Related Families Zahra Razavi*1, MD; MohammadMehdi Taghdiri¹, MD; Fatemeh Eghbalian¹, MD; Nooshin Bazzazi², MD 1. Department of Pediatrics, Hamadan University of Medical Sciences, IR Iran 2. Department of Ophthalmology, Hamadan University of Medical Sciences, IR Iran Received: Feb 07, 2009; Final Revision: Apr 27, 2009; Accepted: May 06, 2009 Abstract Background: Allgrove syndrome is a rare autosomal recessive condition characterized by adrenal insufficiency, achalasia, alacrima and occasionally autonomic disturbances. Mutations in the AAAS gene, on chromosome 12q13 have been implicated as a cause of this disorder. Case(s) Presentation: We present various manifestations of this syndrome in two related families each with two affected siblings in which several members had symptoms including reduced tear production, mild developmental delay, achalasia, neurological disturbances and also premature loss of permanent teeth in two of them, Conclusion: The importance of this report is dental involvement (loss of permanent teeth) in Allgrove syndrome that has not been reported in literature. Iranian Journal of Pediatrics, Volume 20 (Number 1), March 2010, Pages: 101106 Key Words: Achalasia, Adrenocortical Insufficiency, Alacrimia (Allgrove, triple‐A) Protein, Human; AAAS Protein, Human; Teeth; Allgrove Syndrome; Triple A Syndrome Protein, Human Introduction autonomic disturbances associated with Allgrove syndrome leading one author to In 1978 Allgrove and colleagues described 2 recommend the name 4A syndrome (adreno‐ unrelated pairs of siblings with achalasia and cortical insufficiency, achalasia of cardia, ACTH insensivity, three had impaired alacrima and autonomic abnormalities)[2‐4]. -
Prevalence and Incidence of Rare Diseases: Bibliographic Data
Number 1 | January 2019 Prevalence and incidence of rare diseases: Bibliographic data Prevalence, incidence or number of published cases listed by diseases (in alphabetical order) www.orpha.net www.orphadata.org If a range of national data is available, the average is Methodology calculated to estimate the worldwide or European prevalence or incidence. When a range of data sources is available, the most Orphanet carries out a systematic survey of literature in recent data source that meets a certain number of quality order to estimate the prevalence and incidence of rare criteria is favoured (registries, meta-analyses, diseases. This study aims to collect new data regarding population-based studies, large cohorts studies). point prevalence, birth prevalence and incidence, and to update already published data according to new For congenital diseases, the prevalence is estimated, so scientific studies or other available data. that: Prevalence = birth prevalence x (patient life This data is presented in the following reports published expectancy/general population life expectancy). biannually: When only incidence data is documented, the prevalence is estimated when possible, so that : • Prevalence, incidence or number of published cases listed by diseases (in alphabetical order); Prevalence = incidence x disease mean duration. • Diseases listed by decreasing prevalence, incidence When neither prevalence nor incidence data is available, or number of published cases; which is the case for very rare diseases, the number of cases or families documented in the medical literature is Data collection provided. A number of different sources are used : Limitations of the study • Registries (RARECARE, EUROCAT, etc) ; The prevalence and incidence data presented in this report are only estimations and cannot be considered to • National/international health institutes and agencies be absolutely correct. -
French Clinical Practice Guidelines for Moyamoya Angiopathy
NEUROL-1879; No. of Pages 12 r e v u e n e u r o l o g i q u e x x x ( 2 0 1 8 ) x x x – x x x Available online at ScienceDirect www.sciencedirect.com Practice guidelines French clinical practice guidelines for Moyamoya angiopathy a, b c,1 d,1 D. Herve´ *, M. Kossorotoff , D. Bresson , T. Blauwblomme , e,1 f g h i M. Carneiro , E. Touze , F. Proust , I. Desguerre , S. Alamowitch , j k l m n J.-P. Bleton , A. Borsali , E. Brissaud , F. Brunelle , L. Calviere , o p q r M. Chevignard , G. Geffroy-Greco , S. Faesch , M.-O. Habert , s t a u v H. De Larocque , P. Meyer , S. Reyes , L. Thines , E. Tournier-Lasserve , a H. Chabriat a De´partement de neurologie, centre de re´fe´rence des maladies vasculaires rares du cerveau et de l’œil (CERVCO), groupe hospitalier Saint-Louis-Lariboisie`re-Fernand-Widal, 2, rue Ambroise-Pare´, 75010 Paris, France b Centre national de re´fe´rence de l’AVC de l’enfant, hoˆpital universitaire Necker-Enfants malades, AP–HP, 149, rue de Se`vres, 75015 Paris, France c Service de neurochirurgie, groupe hospitalier Saint-Louis-Lariboisie`re-Fernand-Widal, 2, rue Ambroise-Pare´, 75010 Paris, France d Service de neurochirurgie pe´diatrique, hoˆpital universitaire Necker–Enfants-Malades, AP–HP, 149, rue de Se`vres, 75015 Paris, France e Neurologie pe´diatrique, hoˆpital Femme-Me`re-Enfant, hospices Civils-de-Lyon, 59, boulevard Pinel, 69677 Bron, France f Service de neurologie, Normandie universite´, Unicaen, Inserm U1237, CHU Caen-Normandie, avenue de la Coˆte-de- Nacre, 14033 Caen, France g Service de neurochirurgie, -
Current Affairs Q&A
Current Affairs Q&A PDF This is Paid PDF provided by AffairsCloud.com, Our team is working hard in back end to provide quality PDF. If you not buy this paid PDF subscription plan, we kindly request you to buy pdf to avail this service. Help Us To Grow & Provide Quality Service Subscribe(Buy) Current Affairs PDF 2019 - Pocket, Study and Q&A (English & Hindi) Current Affairs Q&A PDF - September 2019 Table of Contents INDIAN AFFAIRS ................................................................................................................................................................................... 2 INTERNATIONAL AFFAIRS ............................................................................................................................................................ 59 BANKING & FINANCE ....................................................................................................................................................................... 87 ECONOMY & BUSINESS ................................................................................................................................................................. 112 AWARDS & RECOGNITIONS ........................................................................................................................................................ 128 APPOINTMENTS & RESIGNS ....................................................................................................................................................... 154 SCIENCE & TECHNOLOGY ........................................................................................................................................................... -
Orphanet Report Series Rare Diseases Collection
Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic -
Dieulafoy's Lesion Associated with Megaesophagus
vv ISSN: 2455-2283 DOI: https://dx.doi.org/10.17352/acg CLINICAL GROUP Received: 21 September, 2020 Case Report Accepted: 06 October, 2020 Published: 07 October, 2020 *Corresponding author: Valdemir José Alegre Salles, Dieulafoy’s Lesion Associated Assistant Doctor Profesor, Department of Medicine, University of Taubaté, Brazil, Tel: +55-15-12-3681-3888; Fax: +55-15-12-3631-606; E-mail: with Megaesophagus Keywords: Dieulafoy’s lesion; Esophageal Valdemir José Alegre Salles1,2*, Rafael Borges Resende3, achalasia; Haematemesis; Endoscopic hemoclip; Gastrointestinal bleeding 3 2,4 Gustavo Seiji , and Rodrigo Correia Coaglio https://www.peertechz.com 1Assistant Doctor Profesor, Department of Medicine, University of Taubaté, Brazil 2General Surgeon at the Regional Hospital of Paraíba Valley, Taubaté, Brazil 3Endoscopist Physician at the Regional Hospital of Paraíba Valley, Taubaté, Brazil 4Assistant Profesor, Department of Medicine, University of Taubaté, Brazil A 31-years-old male patient, with no previous symptoms, admitted to the ER with massive hematemesis that started about 2 hours ago and already with hemodynamic repercussions. After initial care with clinical management for compensation, and airway protection (intubation) he underwent esophagogastroduodenoscopy (EGD), which was absolutely inconclusive due to the large amount of solid food remains and clots already in the proximal esophagus with increased esophageal gauge. After a 24 hours fasting, and 3 inconclusive EGD, since we don’t have the availability of an overtube, we decided to use a calibrated esophageal probe (Levine 22) and to maintain lavage and aspiration of the contents, until the probe returned clear. In this period, the patient presented several episodes of hematimetric decrease and melena, maintaining hemodynamic stability with intensive clinical support. -
Megaesophagus in Congenital Diaphragmatic Hernia
Megaesophagus in congenital diaphragmatic hernia M. Prakash, Z. Ninan1, V. Avirat1, N. Madhavan1, J. S. Mohammed1 Neonatal Intensive Care Unit, and 1Department of Paediatric Surgery, Royal Hospital, Muscat, Oman For correspondence: Dr. P. Manikoth, Neonatal Intensive Care Unit, Royal Hospital, Muscat, Oman. E-mail: [email protected] ABSTRACT A newborn with megaesophagus associated with a left sided congenital diaphragmatic hernia is reported. This is an under recognized condition associated with herniation of the stomach into the chest and results in chronic morbidity with impairment of growth due to severe gastro esophageal reflux and feed intolerance. The infant was treated successfully by repair of the diaphragmatic hernia and subsequently Case Report Case Report Case Report Case Report Case Report by fundoplication. The megaesophagus associated with diaphragmatic hernia may not require surgical correction in the absence of severe symptoms. Key words: Congenital diaphragmatic hernia, megaesophagus How to cite this article: Prakash M, Ninan Z, Avirat V, Madhavan N, Mohammed JS. Megaesophagus in congenital diaphragmatic hernia. Indian J Surg 2005;67:327-9. Congenital diaphragmatic hernia (CDH) com- neonate immediately intubated and ventilated. His monly occurs through the posterolateral de- vital signs improved dramatically with positive pres- fect of Bochdalek and left sided hernias are sure ventilation and he received antibiotics, sedation, more common than right. The incidence and muscle paralysis and inotropes to stabilize his gener- variety of associated malformations are high- al condition. A plain radiograph of the chest and ab- ly variable and may be related to the side of domen revealed a left sided diaphragmatic hernia herniation. The association of CDH with meg- with the stomach and intestines located in the left aesophagus has been described earlier and hemithorax (Figure 1). -
Peroral Endoscopic Myotomy for the Treatment of Achalasia: a Clinical Comparative Study of Endoscopic Full-Thickness and Circular Muscle Myotomy
Peroral Endoscopic Myotomy for the Treatment of Achalasia: A Clinical Comparative Study of Endoscopic Full-Thickness and Circular Muscle Myotomy Quan-Lin Li, MD, Wei-Feng Chen, MD, Ping-Hong Zhou, MD, PhD, Li-Qing Yao, MD, Mei-Dong Xu, MD, PhD, Jian-Wei Hu, MD, Ming-Yan Cai, MD, Yi-Qun Zhang, MD, PhD, Wen-Zheng Qin, MD, Zhong Ren, MD, PhD BACKGROUND: A circular muscle myotomy preserving the longitudinal outer esophageal muscular layer is often recommended during peroral endoscopic myotomy (POEM) for achalasia. However, because the longitudinal muscle fibers of the esophagus are extremely thin and fragile, and completeness of myotomy is the basis for the excellent results of conventional surgical myotomy, this modi- fication needs to be further debated. Here, we retrospectively analyzed our prospectively main- tained POEM database to compare the outcomes of endoscopic full-thickness and circular muscle myotomy. STUDY DESIGN: According to the myotomy depth, 103 patients with full-thickness myotomy were assigned to group A, while 131 patients with circular muscle myotomy were assigned to group B. Symptom relief, procedure-related parameters and adverse events, manometry outcomes, and reflux complications were compared between groups. RESULTS: The mean operation times were significantly shorter in group A compared with group B (p ¼ 0.02). There was no increase in any procedure-related adverse event after full-thickness myotomy (all p < 0.05). During follow-up, treatment success (Eckardt score 3) persisted for 96.0% (95 of 99) of patients in group A and for 95.0% (115 of 121) of patients in group B (p ¼ 0.75). -
Albany Med Conditions and Treatments
Albany Med Conditions Revised 3/28/2018 and Treatments - Pediatric Pediatric Allergy and Immunology Conditions Treated Services Offered Visit Web Page Allergic rhinitis Allergen immunotherapy Anaphylaxis Bee sting testing Asthma Drug allergy testing Bee/venom sensitivity Drug desensitization Chronic sinusitis Environmental allergen skin testing Contact dermatitis Exhaled nitric oxide measurement Drug allergies Food skin testing Eczema Immunoglobulin therapy management Eosinophilic esophagitis Latex skin testing Food allergies Local anesthetic skin testing Non-HIV immune deficiency disorders Nasal endoscopy Urticaria/angioedema Newborn immune screening evaluation Oral food and drug challenges Other specialty drug testing Patch testing Penicillin skin testing Pulmonary function testing Pediatric Bariatric Surgery Conditions Treated Services Offered Visit Web Page Diabetes Gastric restrictive procedures Heart disease risk Laparoscopic surgery Hypertension Malabsorptive procedures Restrictions in physical activities, such as walking Open surgery Sleep apnea Pre-assesment Pediatric Cardiothoracic Surgery Conditions Treated Services Offered Visit Web Page Aortic valve stenosis Atrial septal defect repair Atrial septal defect (ASD Cardiac catheterization Cardiomyopathies Coarctation of the aorta repair Coarctation of the aorta Congenital heart surgery Congenital obstructed vessels and valves Fetal echocardiography Fetal dysrhythmias Hypoplastic left heart repair Patent ductus arteriosus Patent ductus arteriosus ligation Pulmonary artery stenosis -
Management of Stroke in Neonates and Children: a Scientific Statement from the American Heart Association/American Stroke Association
UCSF UC San Francisco Previously Published Works Title Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association. Permalink https://escholarship.org/uc/item/0sw5j7c1 Journal Stroke, 50(3) ISSN 0039-2499 Authors Ferriero, Donna M Fullerton, Heather J Bernard, Timothy J et al. Publication Date 2019-03-01 DOI 10.1161/str.0000000000000183 Peer reviewed eScholarship.org Powered by the California Digital Library University of California AHA/ASA Scientific Statement Management of Stroke in Neonates and Children A Scientific Statement From the American Heart Association/American Stroke Association The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Donna M. Ferriero, MD, MS, FAHA, Co-Chair; Heather J. Fullerton, MD, MAS, Co-Chair; Timothy J. Bernard, MD, MSCS; Lori Billinghurst, MD, MSc, FRCPC; Stephen R. Daniels, MD, PhD; Michael R. DeBaun, MD, MPH; Gabrielle deVeber, MD; Rebecca N. Ichord, MD; Lori C. Jordan, MD, PhD, FAHA; Patricia Massicotte, MSc, MD, MHSc; Jennifer Meldau, MSN; E. Steve Roach, MD, FAHA; Edward R. Smith, MD; on behalf of the American Heart Association Stroke Council and Council on Cardiovascular and Stroke Nursing Purpose—Much has transpired since the last scientific statement on pediatric stroke was published 10 years ago. Although stroke has long been recognized as an adult health problem causing substantial morbidity and mortality, it is also an important cause of acquired brain injury in young patients, occurring most commonly in the neonate and throughout childhood. This scientific statement represents a synthesis of data and a consensus of the leading experts in childhood cardiovascular disease and stroke.